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SUMMARY ∑ Carotid endarterectomy (CEA) is widely used in the management of high grade carotid
stenosis. It is a surgical procedure requiring general anesthesia and is suitable only for lesions located
at or close to the carotid bifurcation. It has complications, including stroke, death, cranial nerve palsies,
wound hematoma and cardiac complications. The risk of complications is increased in patients with
recurrent carotid artery stenosis following CEA, in subjects undergoing radiotherapy to the neck,
and in the presence of cardiopulmonary disease. The drawbacks of CEA have led physicians to search
for alternative treatment options. Carotid angioplasty and stenting (CAS) is less invasive than CEA.
The method is particularly suitable for the treatment of recurrent stenosis after previous CEA and
distal internal artery stenosis, which is inaccessible for CEA. CAS does not cause cranial nerve pal-
sies. Moreover, it does not require general anesthesia and carries a lower morbidity and mortality in
patients with severe cardiopulmonary disease. The complications of CAS include stroke due to distal
embolization of a plaque or thrombus dislodged during the procedure, abrupt vessel occlusion due to
thrombosis, dissection or vasospasm, and restenosis due to intimal hyperplasia. CAS is a relatively
new procedure and it is essential to establish its efficacy and safety before it is introduced widely into
clinical practice. In Slovenia, we have also started with carotid angioplasty by the study Slovenian
Carotid Angioplasty Study (SCAS). Acording to our initial experience in 17 patients, CAS could
gain more importance in stroke prevention with proper selection of patients with brain ischemia and
improved cerebral protection during the procedure.
Introduction
Stroke is an important public health problem and the
third most common cause of death, after heart diseases
and cancer1. In Slovenia, stroke incidence, measured as a
first ever  stroke per 100 000 population, is 190.5 and
mortality rate is 19.3%2. The proportion of ischemic
stroke increases with age (33% before 45 and 80% after
50). Some 20% to 30% of all cases are supposed to be due
to carotid stenosis3. The most common cause of carotid
stenosis is atherosclerosis. The mechanism of brain is-
chemia has been thought to imply either a direct hemo-
dynamic impact on the cerebral blood circulation or in-
direct as a source of thromboembolic material4. Three
possible treatement modalities are available to prevent
stroke caused by carotid  stenosis. First is medical treat-
ment, second surgical treatment, and third the newest
approach, endovascular treatment by carotid angioplasty
and stenting (CAS).
Platelet antiaggregants such as acetylsalicylic acid or
ticlopidine reduce the risk of stroke5,6. Recently, preven-
tive treatment with clopidogrel in combination with ace-
tylsalicylic acid has been recomended7. Correcting the risk
factors such as smoking, obesity, dyslipidemia, hyperten-
sion, and diabetes is necessary.
In surgical approach, the atheromatous plaque is ex-
tirpated, removed, and the artery is sutured. The first ope-
ration on carotid artery, carotid endarterectomy (CEA),
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was performed by DeBakey in 19538. The number of the
procedures increased in the following years. In 1984, 120
000 CEA operations were performed9, wherafter the
number of CEA began to decrease because of uncertain
effectiveness10. In 1991, randomized prospective surgical
trials, North American Symptomatic Carotid Endarter-
ectomy Trial (NASCET)11 and European Carotid Sur-
gery Trial (ECST)12 demonstrated a significant stroke risk
reduction by CEA compared with medical treatment in
symptomatic patients with carotid stenosis greater than
70%. Reassessment of results by the American Heart
Association (AHA) Stroke Council indicates that CEA
was three times as effective as medical treatment in reduc-
ing the frequency of stroke13. However, CEA carries a risk
of complications. The benefit of CEA depends on main-
taining a low complication rate. Most important compli-
cations during the procedure are perioperative stroke and
death. Combined stroke and death rates exceeding 3% for
patients with asymptomatic stenosis and 6% for patients
with symptomatic stenosis would eliminate the benefit in
stroke reduction14. Postendarterectomy restenosis should
also be mentioned, since it is not rare. The rate is esti-
mated between 1.2% and 23.9%, depending on the opera-
tive technique15. The risk of complications associated with
reoperation is high16. The rate of cranial nerve injuries due
to neck incision is 7.6% to 27%17.
CEA is the ‘gold standard’ so far, but it is not with-
out risks and limits as regards high risk patients (elderly
patients, patients suffering from coronary diseases, respi-
ratory insufficiency...), supra-aortic lesions located in the
upper section, and carotid lesions associated with severe
intracranial lesions. Therefore, less invasive CAS seems to
have its place in the treatment of carotid stenoses.
CAS has a history of more than 20 years. After experi-
ments on on animal model, in 1977 Mathias proposed the
treatment of carotid stenosis using angioplasty for the first
time18. The first carotid angioplasty was performed in
1980 by Kerber19. Carotid angioplasty with or without
stenting has been investigated during the last two decades.
This procedure has not received wide acceptance because
of the risk of embolic stroke during the procedure. Till
1997, the rate of perioperative stroke following CAS with-
out cerebral protection ranged from 5.3% to 8.2%20,21.
Initial results were criticized for the high rate of neuro-
logic complications22. The main cause of perioperative
complications are thought to be embolic particles released
from the carotid plaque during angioplasty23. In 1990,
Theron, the ‘father’ of a cerebral protection, developed and
advocated the use of a cerebral protection device during
CAS24. The risk of embolization and the need for cere-
bral protection during CAS was confirmed later25.
The safety and efficacy of CAS with cerebral protec-
tion versus CEA were compared in a prospective random-
ized trial Carotid Revascularization Endarterectomy ver-
sus Stent Trial (CREST), launched at the beginning of
200126.
In Slovenia, we have also started with CAS by setting
up the study Slovenian Carotid Angioplasty Study




The study was designed as a prospective clinical trial
conducted over a period of 2 years in 60 patients enrolled
according to well-defined inclusion and exclusion crite-
ria. The patients were evaluated independently by a neu-
rologist prior to and during the procedure and follow-up
examinations performed at 1, 6, 12 and 24 months. Evalu-
ation of cerebral protection devices was incorporated in
the study.
The safety of CAS was assessed on the basis of acute
procedural success and occurrence of major clinical events
during or within 30 days of the procedure. The efficacy
of CAS was determined with respect to minor ipsilateral
neurologic events, major stroke and death occurring dur-
ing or within 30 days of the procedure, and recurrent
stenosis established within 24 months of CAS.
Oral and written information on the study was pro-
vided to all patients, and a written, witnessed informed
consent was obtained from each of them. The study was
approved by the National Medical Ethics Committee.
Patients
We performed CAS in 17 patients aged 69 to 82 years,
12 male and five female. All patients were symptomatic
with stenosis greater than 70%. Ten patients had suffered
transient ischemic attacks, four patients minor stroke and
three patients amaurosis fugax. Seven patients had stenosis
of the right internal carotid artery, eight of the left inter-
nal carotid artery, and two of the right common carotid
artery. Two patients had occlusion of the contralateral
carotid artery. In the first six patients we did not use ce-
rebral protection devices. In the other 11 patients cerebral
protection filter devices were used.
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Procedure
All patients were taking aspirin, 325 mg/d, and
clopidogrel (75 mg/d) starting 7 days before the proce-
dure. Heparin, given as an intra-arterial bolus, was titrated
to maintain the activated clotting time between 200 and
250 seconds. The procedures were performed in local
anesthesia. Neurologic status was monitored. Atropine
(0.5-1 mg) was given as required during balloon inflation.
Heart rate and blood pressure were monitored through-
out the intervention.
Percutaneous access was gained through the femoral
artery. Selective catheterization of carotid arteries was
performed with standard techniques. Diagnostic angiog-
raphy visualized the origins of the brachiocephalic arter-
ies from the aortic arch, both carotid bifurcations, both
vertebral arteries, intracranial parts of both carotid arter-
ies and the dominant vertebral artery. Once diagnostic
angiography was completed and the stenotic internal ca-
rotid artery was identified, a 5F catheter was advanced
using a 0.035-inch glide wire (Terumo Radiofocus Guide
Wire, Terumo, Inc.) into the ipsilateral external carotid
artery. The glide wire was  withdrawn and replaced with
an extra stiff 0.035-inch exchange wire (Extra Stiff
Amplatz Wire, 260 cm; Cook, Inc.). The 5F catheter was
withdrawn, and an 8F 90-cm guiding sheath (Carotid
Vista Brite Tip; Cordis, Inc.) was advanced into the com-
mon carotid artery over the exchange Amplatz wire,
which was anchored in the external carotid artery. Carotid
angiography was performed again to measure the vessel
diameter to facilitate the sizing of balloons, stents and
cerebral protection filter devices. In patients without ce-
rebral protection, stenoses were then crossed with flexible
coronary guidewires (V-18 Control Wire; Boston Scien-
tific Corp, Watertown, Mass). Eleven patients underwent
CAS with a cerebral protection filter device Angioguard
(Cordis, Inc): a low-profile guidewire-based, filter-type
device (4F) that was placed in the distal ICA after cross-
ing the stenotic lesion. It captured embolic debris while
maintaining distal perfusion. After that we started with
the intervention on stenosis. The size of the initial
angioplasty balloon was dictated by the severity of steno-
sis. Very severe lesions were predilated with low-profile
coronary balloons ( Bypass Speedy Monorail Catheter,
Boston Scientific Corp ); in case of less severe lesions, the
initial dilatation might be performed with a definitive
balloon sized to the distal normal artery. A Carotid
Wallstent Monorail (Boston Scientific Corp) was de-
ployed across the lesion. The stent was  dilated at high
pressure (14 to 16 atm) to firmly embed it into the vessel
wall. After that, the filter with trapped emboli was re-
moved and the procedure was finished. Completion an-
giography was performed on the ipsilateral intracranial
vessels. Patients were transferred to the intensive care unit,
after which the sheaths were removed. Patients were dis-
charged on either the first or second day after the proce-
dure. Clopidogrel was continued for 3 weeks, and aspirin
was continued permanently.
Results
Procedural results are summarized in Table 1. Tech-
nical success (<30% residual stenosis) was achieved in all
cases. In 14 patients, no residual stenosis was found,
whereas 15% residual stenosis peristed in two, and 30%
residual stenosis in one patient.
In one patient (Patient 5, Table 1), hyperperfusion
syndrome occurred. It occurred in a 72-year-old female
with carotid stenosis of more than 90%, who had suffered
amaurosis fugax in the past. Stenting was performed
succesfully without residual stenosis and immediate com-
plications (Fig. 1). On day 5 after CAS, generalized sei-
zure with Tod’s hemiparesis on the right side occurred.
Upon admission, we performed brain CT, which showed
a small subarachnoid hemorrhage frontally on the left side
(Fig. 2). She recovered completely after a week.
Periprocedural stroke occurred in one patient (Patient
6, Table 1). It was a 67-year-old male with a previous
minor stroke and 90% stenosis of the left internal carotid
artery due to a lipid-laden plaque and occluded right ca-
rotid artery. In this case, we used a cerebral protective fil-
ter. CAS was successfully performed (Fig. 3). Cerebral
embolism occurred during filter removal. He developed
aphasia and hemiplegia. The embolus at the middle ce-
rebral artery bifurcation was dissolved by intra-arterial
thrombolysis using rTPA (Fig. 4).
In 15 patients, CAS was performed without compli-
cations. In all patients, follow-up (average follow-up pe-
riod of 3 months) revealed no transient ischemic attacks
or new strokes. All patients remained at their neurologic
baseline. Long-term clinical or imaging follow-up data are
not yet available.
Discussion
Over the last years angioplasty has been successfully
used in coronary and peripheral disorders and has also
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Table 1. Procedure results in 17 patients
Stenosis
%
Pt Vessel Symptoms Age, y CLO Pre Post Procedure Severe Comments
stroke CAD
1 R ICA TIA 74 90 0 No Yes
2 L ICA Stroke 72 Yes 99 0 No No
3 R ICA TIA 63 70 0 No No
4 R CCA TIA 68 80 0 No Yes
5 L ICA Amaurosis fugax 72 95 0 No No After five days, an episode of
seizure and transitory Tod’s
hemiparesis occurred. CT of the
brain showed small subarach-
noid hemorrhage on the left
frontal side. After a week, she
recovered completely.
6 L ICA Stroke 67 Yes 87 0 Yes Yes Occlusion of right ICA.
Cerebral embolism occurred
during filter removal. He
became aphasic and had right
hemiplegia. We dissolved
embolus at MCA bifurcation
with intra-arterial thrombolysis
using rTPA, but some
hemiparesis persisted.
7 R CCA TIA 66 80 0 No No Right iliac stenting in the same
procedure.
8 L ICA Amaurosis fugax 70 Yes 75 0 No Yes
9 R ICA Stroke 64 90 15 No No
10 L ICA TIA 68 76 0 No No
11 RICA TIA 82 80 0 No Yes
12 R ICA TIA 68 71 0 No No
13 L ICA TIA 82 75 0 No Yes
14 R ICA TIA 61 73 0 No No
15 L ICA Stroke 76 99 30 No Yes
16 R ICA Amaurosis fugax 57 85 0 No No
17 L ICA TIA 53 75 15 No No
Pt, patient; CLO, contralateral carotid occlusion; CAD, coronary artery disease; R, right; ICA, internal carotid artery; L, left; CCA, common
carotid artery; MCA, middle cerebral artery;
*From patient 6 on, cerebral protection filter device used.
carotid angioplasty is to prevent cerebrovascular neuro-
logic events and not to overshadow surgery. It could be an
alternative or a complement to surgery if results are com-
parable or better. Indications must be defined through
been applied at the carotid level. Throughout the world,
several teams are actively engaged in research in order to
determine the indications, suitable techniques, adjunct
treatments, and follow-up conditions. The final aim of
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randomized multi-center studies and are currently much
debated. Some would like them to be limited to high risk
patients, restenosis, radiation-induced lesions, or lesions
located in the upper internal carotid artery near the skull,
while others would like them to be much larger, includ-
ing lesions of the carotid bifurcation27. Lately cerebral
protection devices have the potential to enhance the safety
of CAS28. First report of a larger series by Wholey29 shows
the rate of perioperative complications after CAS with
cerebral protection to be 1.6%, which is significantly lower
than with CEA and CAS without cerebral protection.
Now we treat all patients using a cerebral protection
filter device. In all filters, we found embolic material. In
two cases, filters were occluded due to a massive amount
of embolic material. We suppose that in such cases a high
risk of complications exists, and it is very important to
know the type of plaque that can dislodge a large amount
of embolic material. For the evaluation of plaque compo-
Fig. 1. Digital subtraction angiography. Lateral views of the left
carotid artery bifurcation. A) High grade circumferential, atheroscle-
rotic stenosis of the internal carotid artery origin before CAS. B) No
residual stenosis after CAS.
Fig. 2. CT of the brain shows small subarachnoid hemorrahage in
the left frontal region.
Fig. 4. Digital subtraction angiography. Anteroposterior views of the
left intracranial internal carotid artery with branches. A) Acute oc-
clusion of the left middle cerebral artery at the bifurcation. B) Re-
canalization of the occlusion after intra-arterial thrombolysis.
Fig. 3. Digital subtraction angiography. Lateral views of the left ca-
rotid artery bifurcation. A) 90% stenosis of the left internal carotid
artery before CAS. B) Cerebral protection filter device during CAS.
C) No residual stenosis after CAS.
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sition we performed ultrasound. We did not perform CAS
in patients with echolucent plaques (type 1) due to high
embolic risk30. Fibrous plaques seem to carry a very low
risk of rupture and embolization. We expect to learn more
about plaque composition using MRI. MR additionally
shows the thickness of fibrous cap and pre-existent rup-
tures of the plaque31. By demonstrating thick or thin fi-
brous cap of the plaque and correlating data with the
amount of emboli trapped in the filter, we could be able
to analyze the risk of periprocedural complications. This
information would enable better selection of patients for
CAS. According to our initial experience in 17 patients,
CAS could gain more importance in stroke prevention
with proper selection of patients and improved cerebral
protection during the procedure.
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Saæetak
KAROTIDNA ANGIOPLASTIKA S CEREBRALNOM ZA©TITOM
Z. MiloπeviË, B. Ævan, M. Zaletel i M. ©urlan
Karotidna endarterektomija (CEA) u πirokoj je uporabi pri lijeËenju karotidne stenoze visokog stupnja. Kirurπki zahvat
obavlja se u opÊoj anesteziji, a primjenjuje se samo pri oπteÊenjima na raËviπtu karotide ili u njegovoj neposrednoj blizini.
Komplikacije koje se mogu pojaviti obuhvaÊaju moædani udar, smrt, paralizu kranijskih æivaca, hematom na mjestu rane i
srËane komplikacije. Rizik komplikacija poveÊan je u bolesnika s recidivirajuÊom stenozom karotidne arterije nakon CEA, u
bolesnika u kojih je primijenjena radioterapija u podruËju vrata te u bolesnika s kardiopulmonalnom bolesti. Nedostatci CEA
potaknuli su lijeËnike da potraæe alternativne naËine lijeËenja. Karotidna angioplastika uz postavljanje stenta (CAS) manje je
invazivna metoda od CEA. Ona je poglavito prikladna za lijeËenje recidivirajuÊih stenoza nakon prethodne CEA te za lijeËenje
stenoze distalnog dijela unutarnje karotidne arterije koja je nedostupna za CEA. CAS ne uzrokuje paralizu kranijskih æivaca.
Usto, nije nuæna opÊa anestezija, a u bolesnika s teπkom kardiopulmonalnom bolesti pobol i smrtnost su manji. U komplikacije
CAS pripadaju moædani udar zbog distalne embolizacije plaka ili odvajanja tromba tijekom postupka, nagla okluzija krvne æile
zbog tromboze, disekcija ili vazospazam te ponovna stenoza zbog hiperplazije intime. CAS je razmjerno nov postupak, pa je
nuæno utvrditi njegovu djelotvornost i sigurnost prije nego πto se uvede u πiroku kliniËku uporabu. U Sloveniji smo zapoËeli
s istraæivanjem karotidne angioplastike u okviru projekta “Slovenian Carotid Angioplasty Study (SCAS)”. Prema naπim prvim
iskustvima u 17 bolesnika, CAS bi se mogao pokazati vaænim u prevenciji moædanog udara, uz dobar odabir bolesnika s
moædanom ishemijom i uz bolju cerebralnu zaπtitu tijekom postupka.
erosclerotic carotid plaque in vivo with high-resolution magnetic
resonance imaging. Circulation 2000;102:959-64.
